BioSpace News Archive

U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patientsbwith Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes

MR Solutions’ latest liquid helium free PET-MR preclinical imaging system for the molecular research community was the subject of talks and papers on simultaneous PET-MR imaging at the World Molecular Imaging Congress held in Montreal in September.

TherOx announces key data presentations and company-sponsored events for SuperSaturated Oxygen (SSO2) Therapy at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium Sept. 25-29 at the Moscone Center in San Francisco.

Toujeo® improved blood sugar control vs insulin degludec in adults with type 2 diabetes and moderate-to-severe kidney impairment • Secondary analyses expand results from BRIGHT head-to-head clinical trial

Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome, is due to participate in several upcoming conferences between September and December, 2019.

A new study has shown the power of genetic testing to pick out the best drugs for children with cancer to extend and improve their lives – signalling a new era of precision medicine for young patients.

Switching to Toujeo® in a real-world setting produced a 27% reduction in risk of low blood sugar requiring an emergency department visit in patients at high risk ∙ New analyses extend DELIVER and LIGHTNING Real-World Evidence programs

An industry first, the volunteer committee will evaluate unique patient needs and advise PRA on how clinical trials can be adapted for rare disease patients

IBA announces the launch of the development of the world’s first cyclotron-based carbon therapy system in Caen, France through its subsidiary Normandy Hadrontherapy, in collaboration with the Normandy Region and several other private and public players, including SAPHYN.